Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer
February 22, 2021 02:00 ET
|
Immunicum AB
Pressmeddelande 22 februari 2021 Immunicum meddelar lovande resultat avseende överlevnad i fas II-studien MERECA med ilixadencel i njurcancer - Medianöverlevnad för patientgruppen som behandlades...
Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer
February 22, 2021 02:00 ET
|
Immunicum AB
Press Release 22 February 2021 Immunicum Announces Encouraging Signs of Survival Benefit in Phase II MERECA Trial of Ilixadencel in Kidney Cancer -- Median Overall Survival (OS) for the...
Organicell Phase I/II Clinical Trial Update
August 18, 2020 07:00 ET
|
ORGANICELL REGENERATIVE MEDICINE, INC
MIAMI, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB: BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,...
To Fully Focus on Cellectis, Dr. André Choulika Retires From Calyxt’s Board of Directors
July 06, 2020 17:19 ET
|
Cellectis Inc.
NEW YORK, July 06, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS) - André Choulika, Ph.D., Cellectis’ Chairman and CEO, announces that he will focus all his energy on...
Organicell Reports Positive Results from Compassionate Use of Organicell Flow in Severely Ill COVID-19 Patients
May 27, 2020 07:00 ET
|
ORGANICELL REGENERATIVE MEDICINE, INC
MIAMI, May 27, 2020 (GLOBE NEWSWIRE) -- Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies,...
Abeona Announces FDA Grants RMAT Designation to ABO-102 Gene Therapy in MPS IIIA
April 23, 2018 08:15 ET
|
Abeona Therapeutics Inc.
First Gene Therapy Using AAV Approach Granted Regenerative Medicine Advanced Therapy Designation NEW YORK and CLEVELAND, April 23, 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics...
Abeona Therapeutics Enrolls First Patient in ABO-101 Phase 1/2 Clinical Trial for MPS IIIB
December 20, 2017 08:45 ET
|
Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, Dec. 20, 2017 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene and cell...
Abeona Announces $13.85M Grant from Leading Sanfilippo Syndrome Foundations for Clinical Development of MPS III Gene Therapies
October 16, 2017 08:26 ET
|
Abeona Therapeutics Inc.
Nine global foundations collaborate to grant $13.85 million for the continued advancement of lead Sanfilippo gene therapy programsCompany receives infusion of an additional $5 million from exercise of...
Abeona Therapeutics Enrolls First Two Patients in Pivotal Expansion of Phase 1/2 Clinical Trial in MPS IIIA
October 11, 2017 08:19 ET
|
Abeona Therapeutics Inc
ABO-102 Patients Enrolled in Cohort 3 at 3E13 vg/kgAccelerated enrollments begin with first Patient Enrolled at clinical site in Australia; Patient Screening at Spain site underwayDay 30 results...
Abeona Announces Top-Line One Year Data from ABO-102 MPS IIIA Trial at ARM’s Cell & Gene Meeting on the Mesa
October 06, 2017 08:25 ET
|
Abeona Therapeutics Inc
--Demonstrated durable and significant reduction of underlying disease pathology across multiple clinical measures in Cohort 1 (n=3) compared to controls (n=8-12) --Systemic Biopotency demonstrated...